Research and analysis

RPC opinion: human medicines post-implementation review

Regulatory Policy Committee's opinion of the review of the Human Medicines Regulations 2012 carried out by MHRA.

• From: Regulatory Policy Committee
• Published: 23 March 2026

Documents

RPC opinion: human medicines post-implementation review

HTML

RPC opinion: human medicines post-implementation review

PDF, 175 KB, 7 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email enquiries@rpc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

A second post-implementation review of the Human Medicines Regulations 2012 was led by the Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health and Social Care (DHSC), in consultation with DHSC. The review considered the effectiveness of the regulations from 2017 to 2026.

The Regulatory Policy Committee (RPC) gave a ‘green’ rating to the post implementation review on 24 February 2026. This means that we considered the review to be fit for purpose based on our scrutiny of the evidence and analysis presented.

The RPC’s opinion refers to the evidence and analysis in the review, not the policy itself.

Published 23 March 2026